Actavis Pharmaceuticals

FDA Regulatory Profile

Actavis Pharmaceuticals appears in FDA public data with 1 recall, 0 510(k) clearances, 0 FDA inspections, and 0 compliance actions on record. Its most recent recall (D-175-2013, Class III) was initiated on January 4, 2013.

Summary

Total Recalls
1
510(k) Clearances
0
Inspections
0
Compliance Actions
0

Recent Recalls

NumberClassProductDate
D-175-2013Class IIIbuPROPion Hydrochloride Extended - Release Tablets (XL) 300 mg, 30 tablet bottles, Rx Only, NDC 6776January 4, 2013